Epidemiologic  ||| S:0 E:14 ||| JJ
link  ||| S:14 E:19 ||| NN
between  ||| S:19 E:27 ||| IN
osteoporosis  ||| S:27 E:40 ||| NN
and  ||| S:40 E:44 ||| CC
cardiovascular  ||| S:44 E:59 ||| JJ
disease  ||| S:59 E:67 ||| NN
Osteoporosis  ||| S:67 E:80 ||| NNP
and  ||| S:80 E:84 ||| CC
cardiovascular  ||| S:84 E:99 ||| JJ
disease  ||| S:99 E:107 ||| NN
( ||| S:107 E:108 ||| -LRB-
CVD ||| S:108 E:111 ||| NNP
)  ||| S:111 E:113 ||| -RRB-
are  ||| S:113 E:117 ||| VBP
major  ||| S:117 E:123 ||| JJ
public  ||| S:123 E:130 ||| JJ
health  ||| S:130 E:137 ||| NN
problems ||| S:137 E:145 ||| NNS
,  ||| S:145 E:147 ||| ,
leading  ||| S:147 E:155 ||| VBG
to  ||| S:155 E:158 ||| TO
increased  ||| S:158 E:168 ||| JJ
morbidity  ||| S:168 E:178 ||| NN
and  ||| S:178 E:182 ||| CC
mortality ||| S:182 E:191 ||| NN
.  ||| S:191 E:193 ||| .
Although  ||| S:193 E:202 ||| IN
historically  ||| S:202 E:215 ||| RB
considered  ||| S:215 E:226 ||| VBN
as  ||| S:226 E:229 ||| IN
independent  ||| S:229 E:241 ||| JJ
conditions ||| S:241 E:251 ||| NNS
,  ||| S:251 E:253 ||| ,
clinical  ||| S:253 E:262 ||| JJ
and  ||| S:262 E:266 ||| CC
epidemiological  ||| S:266 E:282 ||| JJ
studies  ||| S:282 E:290 ||| NNS
indicate  ||| S:290 E:299 ||| VBP
that  ||| S:299 E:304 ||| IN
there  ||| S:304 E:310 ||| EX
are  ||| S:310 E:314 ||| VBP
common  ||| S:314 E:321 ||| JJ
pathophysiological  ||| S:321 E:340 ||| JJ
mechanisms  ||| S:340 E:351 ||| NNS
underlying  ||| S:351 E:362 ||| VBG
these  ||| S:362 E:368 ||| DT
diseases ||| S:368 E:376 ||| NNS
.  ||| S:376 E:378 ||| .
In  ||| S:378 E:381 ||| IN
addition  ||| S:381 E:390 ||| NN
to  ||| S:390 E:393 ||| TO
menopause  ||| S:393 E:403 ||| VB
and  ||| S:403 E:407 ||| CC
advanced  ||| S:407 E:416 ||| JJ
age ||| S:416 E:419 ||| NN
,  ||| S:419 E:421 ||| ,
risk  ||| S:421 E:426 ||| NN
factors  ||| S:426 E:434 ||| NNS
for  ||| S:434 E:438 ||| IN
CVD ||| S:438 E:441 ||| NNP
,  ||| S:441 E:443 ||| ,
such  ||| S:443 E:448 ||| JJ
as  ||| S:448 E:451 ||| IN
obesity  ||| S:451 E:459 ||| NN
and  ||| S:459 E:463 ||| CC
diabetes ||| S:463 E:471 ||| NN
,  ||| S:471 E:473 ||| ,
have  ||| S:473 E:478 ||| VBP
also  ||| S:478 E:483 ||| RB
been  ||| S:483 E:488 ||| VBN
associated  ||| S:488 E:499 ||| VBN
with  ||| S:499 E:504 ||| IN
osteoporosis ||| S:504 E:516 ||| NN
.  ||| S:516 E:518 ||| .
Dyslipidemia ||| S:518 E:530 ||| NNP
,  ||| S:530 E:532 ||| ,
oxidative  ||| S:532 E:542 ||| JJ
stress ||| S:542 E:548 ||| NN
,  ||| S:548 E:550 ||| ,
inflammation ||| S:550 E:562 ||| NN
,  ||| S:562 E:564 ||| ,
hyperhomocystinemia  ||| S:564 E:584 ||| NNS
are  ||| S:584 E:588 ||| VBP
associated  ||| S:588 E:599 ||| VBN
to  ||| S:599 E:602 ||| TO
bone  ||| S:602 E:607 ||| VB
remodeling  ||| S:607 E:618 ||| VBG
impairment  ||| S:618 E:629 ||| NNS
and  ||| S:629 E:633 ||| CC
to  ||| S:633 E:636 ||| TO
the  ||| S:636 E:640 ||| DT
atherosclerotic  ||| S:640 E:656 ||| JJ
process  ||| S:656 E:664 ||| NN
and  ||| S:664 E:668 ||| CC
might  ||| S:668 E:674 ||| MD
explain ||| S:674 E:681 ||| VB
,  ||| S:681 E:683 ||| ,
in  ||| S:683 E:686 ||| IN
part ||| S:686 E:690 ||| NN
,  ||| S:690 E:692 ||| ,
the  ||| S:692 E:696 ||| DT
co-existence  ||| S:696 E:709 ||| NN
of  ||| S:709 E:712 ||| IN
osteoporosis  ||| S:712 E:725 ||| NN
and  ||| S:725 E:729 ||| CC
CVD ||| S:729 E:732 ||| NNP
.  ||| S:732 E:734 ||| .
